Bedfont® Scientific Limited Concludes the Shaun in the Heart of Kent Trail by Presenting a CELLER8® Device to a Successful Participant

Viking Ther­a­peu­tics’ dual GLP-1/GIP re­cep­tor ag­o­nist for obe­si­ty showed off pos­i­tive topline da­ta from a Phase II study, with an­a­lysts de­scrib­ing the drug as a

No­var­tis doesn’t want to play the me-too game in obe­si­ty. On Thurs­day, CEO Vas Narasimhan said that try­ing to com­pete in the multi­bil­lion-dol­lar obe­si­ty mar­ket